Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Written Informed Consent~* Subjects with chronic phase chronic myeloid leukemia (CML)~* Subjects resistant/intolerant to imatinib~* Subjects presenting:~  1. ECOG performance status (PS) score 0-2~ 2. Adequate hepatic function~ 3. Adequate renal function~ 4. Adequate lung function~Exclusion Criteria:~* Concurrent malignancy other than CML~* Women who are pregnant or breastfeeding~* Concurrent pleural effusion~* Uncontrolled or significant cardiovascular disease~* A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy.~* Prior therapy with dasatinib~* Subjects with T315I and/or F317L BCR-ABL point mutations

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dasatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).